BioCardia股票讨论区

$美国联合医疗(UTHR.US)$  Phase 3
$Ironwood医药(IRWD.US)$  Phase 3
$Liquidia(LQDA.US)$  Phase 3
$美国联合医疗(UTHR.US)$  Phase 3
$MorphoSys(MOR.US)$  Phase 3
$Immunocore(IMCR.US)$  Phase 3
$Crinetics(CRNX.US)$  Phase 3
$乌龙制药(URGN.US)$  Phase 3
$阿斯利康(AZN.US)$  Phase 3
$阿斯利康(AZN.US)$  Phase 3
$阿斯利康(AZN.US)$  Phase 3
$阿斯利康(AZN.US)$  Phase 3
$Capricor Therapeutics(CAPR.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3...

$BioCardia(BCDA.US)$ Benzinga· just
BioCardia Announces Results From Open Label Roll-In Cohort Of Patients Having Chronic Myocardial Ischemia With Refractory Angina; Showed Avg. Increase In Exercise Tolerance Of 107 Seconds And An Avg. Of 82% Reduction In Angina Episodes At The Primary Six-Month Follow-Up Endpoint

$BioCardia(BCDA.US)$
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

Sunnyvale, Calif., May 1, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.

Stu...

$BioCardia(BCDA.US)$ BioCardia Completes Enrollment of Cardiamp Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-in Cohort

$Travere Therapeutic(TVTX.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$美国联合医疗(UTHR.US)$  Phase 3
$美国联合医疗(UTHR.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3
$Insmed(INSM.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$乌龙制药(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Jaguar Health(JAGX.US)$  Phas...

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$和黄医药(HCM.US)$  Phase 3
$Viracta Therapeutics(VIRX.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$乌龙制药(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Marinus Pharmaceuticals(MRNS.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3...

BioCardia, Inc. (NASDAQ: $BCDA), a leader in the field of regenerative biotechnology.
In a groundbreaking move, BioCardia, Inc. (NASDAQ: $BCDA), a leader in the field of regenerative biotechnology, has announced a strategic partnership with StemCardia, Inc., a cutting-edge stem cell therapy company. This alliance is set to revolutionize the delivery of biotherapeutics, potentially reshaping the future of regenerative medicine. $BioCardia(BCDA.US)$
...

$BioCardia(BCDA.US)$ BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE